Evidence map›Paper›PMID 39727177›Full record

ArticleCurrent medicinal chemistry2025

LncRNA-associated ceRNA Network Revealing the Potential Regulatory Roles of Ferroptosis and Immune Infiltration in Osteosarcoma as well as Construction of the Prognostic Model.

Zhixian Lin, Zhen Wang, Danyan Shao, Jiangfeng Chen, Yunxia Liu, Yongwei Yao

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Role of PANoptosis in cancer: Molecular mechanisms and therapeutic opportunities.Apoptosis : an international journal on programmed cell death · 2025
    Review
  3. Mechanisms underlying methamphetamine-induced disruption of testicular integrity.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  4. PANoptosis: potential new targets and therapeutic prospects in digestive diseases.Apoptosis : an international journal on programmed cell death · 2025
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhixian LinDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China.
Zhen WangDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China.
Danyan ShaoDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China.
Jiangfeng ChenDepartment of Integrated Traditional Chinese & Western Medicine Oncology, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China.
Yunxia LiuDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China.
Yongwei YaoDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China.

Funding

Hangzhou Medical Health Science and Technology Project 20220919Y014Zhejiang Provincial Health Science and Technology Plan 2021KY908
6 · The paper itself

Abstract

backgroundOsteosarcoma (OS) is the most common primary bone malignancy in the world. Increasing studies indicate that long non-coding RNAs (lncRNAs) are involved in ferroptosis and OS progression. Therefore, this study aims to identify ferroptosis- related lncRNAs (FRlncRNAs), explore potential competing endogenous RNA (ceRNA) networks, and establish a new model for predicting OS prognosis.

methodsFirstly, we downloaded data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), University of California, Santa Cruz (UCSC), and FerrDB, and screened for differentially expressed FRlncRNAs (DEFRlncRNAs) between OS patients and healthy controls. Then, we constructed the ceRNA network using the Lncbase 3.0, starBase, miRDB, miRTarBase, and TargetScan databases. Subsequently, prognosis- related DEFRlncRNAs were selected through Cox analysis, and a prognostic model was constructed. Next, the proportions of different immune cells in high and low-risk groups were quantified and evaluated using the "CIBERSORT" algorithm. Finally, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed on prognosis-related DEFRlncRNAs to identify topranked biological processes and pathways.

resultsWe identified 247 DEFRlncRNAs and constructed the ceRNA network comprising 37 lncRNAs, 84 microRNAs (miRNAs), and 865 messenger RNAs (mRNAs). Subsequently, we obtained 8 prognosis-related DEFRlncRNAs (AL645728.1, AL161785.1, LINC00539, AL590764.1, OLMALINC, AC110995.1, AC091180.2, and AL160006.1) and constructed a prognostic model, where metastasis and risk score were identified as important clinical factors for predicting OS prognosis. Additionally, only OLMALINC and AL160006.1 had corresponding target miRNAs in the prognosis-related ceRNA network. Lastly, we revealed the infiltration proportions of different immune cells in OS, with higher proportions of macrophages (M0 and M2 subgroups) and T cells (T cells CD4 memory resting and T cells CD8) observed.

conclusionThis study explored the ferroptosis-related lncRNA-miRNA-mRNA regulatory network in OS, constructed a ferroptosis-related prognostic model, and characterized its association with immune infiltration, providing new insights into the pathological mechanisms and targeted therapy development for OS.

Indexed as

Bone NeoplasmsFerroptosisGene Regulatory NetworksOsteosarcomaRNA, Long NoncodingGene Expression Regulation, NeoplasticHumansMicroRNAsPrognosisRNA, Competitive EndogenousMicroRNAsRNA, Competitive EndogenousRNA, Long NoncodingceRNA networkferroptosisimmune infiltrationLncRNAsOsteosarcomaprognosis.

Identifiers

PMID39727177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.